<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37735010</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>02</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1768-3122</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><Issue>9</Issue><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>La Revue de medecine interne</Title><ISOAbbreviation>Rev Med Interne</ISOAbbreviation></Journal><ArticleTitle>French National Diagnostic and Care Protocol for antiphospholipid syndrome in adults and children.</ArticleTitle><Pagination><StartPage>495</StartPage><EndPage>520</EndPage><MedlinePgn>495-520</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.revmed.2023.08.004</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0248-8663(23)00711-7</ELocationID><Abstract><AbstractText>Antiphospholipid syndrome (APS) is a chronic autoimmune disease involving vascular thrombosis and/or obstetric morbidity and persistent antibodies to phospholipids or certain phospholipid-associated proteins. It is a rare condition in adults and even rarer in children. The diagnosis of APS can be facilitated by the use of classification criteria based on a combination of clinical and biological features. APS may be rapidly progressive with multiple, often synchronous thromboses, resulting in life-threatening multiple organ failure. This form is known as "catastrophic antiphospholipid syndrome" (CAPS). It may be primary or associated with systemic lupus erythematosus (associated APS) and in very rare cases with other systemic autoimmune diseases. General practitioners and paediatricians may encounter APS in patients with one or more vascular thromboses. Because APS is so rare and difficult to diagnosis (risk of overdiagnosis) any suspected case should be confirmed rapidly and sometimes urgently by an APS specialist. First-line treatment of thrombotic events in APS includes heparin followed by long-term anticoagulation with a VKA, usually warfarin. Except in the specific case of stroke, anticoagulants should be started as early as possible. Any temporary discontinuation of anticoagulants is associated with a high risk of thrombosis in APS. A reference/competence centre specialised in autoimmune diseases must be urgently consulted for the therapeutic management of CAPS.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Soci&#xe9;t&#xe9; Nationale Fran&#xe7;aise de M&#xe9;decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Amoura</LastName><ForeName>Z</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Institut E3M, CIMI-Paris, Faculty of medicine, National Reference Centre of Systemic Lupus, antiphospholipid syndrome, and other autoimmune diseases, Sorbonne University, AP-HP, Piti&#xe9; Salp&#xea;tri&#xe8;re, boulevard de l'H&#xf4;pital, 75013 Paris, France. Electronic address: Zahir.amoura@aphp.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bader-Meunier</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Laboratory of Immunogenetics of Paediatric Autoimmune Diseases, Institute Imagine, University Paris Cit&#xe9;, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bal Dit Sollier</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Thrombosis and atherosclerosis research unit, vessels and blood institute (IVS), anticoagulation clinic (CREATIF), Lariboisi&#xe8;re hospital, AP-HP, 75010 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belot</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pediatric Nephrology, Rheumatology, Dermatology, Reference Centre for Rheumatic, AutoImmune and Systemic diseases in children (RAISE), h&#xf4;pital femme m&#xe8;re enfant, CHU de Lyon, Bron, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benhamou</LastName><ForeName>Y</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>National Reference Centre of MicroAngiopathies Thrombotic, Paris, France; Department of Internal Medicine, University Hospital of Rouen, Normandie University, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bezanahary</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Clinical Immunology, centre hospitalier universitaire de Limoges, Limoges, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Institut E3M, CIMI-Paris, Faculty of medicine, National Reference Centre of Systemic Lupus, antiphospholipid syndrome, and other autoimmune diseases, Sorbonne University, AP-HP, Piti&#xe9; Salp&#xea;tri&#xe8;re, boulevard de l'H&#xf4;pital, 75013 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Costedoat-Chalumeau</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Referral Centre for Rare Autoimmune and Systemic Diseases of &#xce;le-de-France, AP-HP, Cochin Hospital, Paris, France; Centre for Epidemiology and Statistics, Institut national de la sant&#xe9; et de la recherche m&#xe9;dicale, French National Institute for Agricultural Research, University Paris Cit&#xe9;, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Darnige</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Biological Hematology Department, Assistance publique-H&#xf4;pitaux de Paris, h&#xf4;pital europ&#xe9;en Georges-Pompidou, Inserm, UMR-S1140, Innovative Therapies in Haemostasis, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drouet</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Thrombosis and atherosclerosis research unit, vessels and blood institute (IVS), anticoagulation clinic (CREATIF), Lariboisi&#xe8;re hospital, AP-HP, 75010 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elefant</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Reference Center for Teratogenic Agents, h&#xf4;pital Armand-Trousseau centre de r&#xe9;f&#xe9;rence sur les agents t&#xe9;ratog&#xe8;nes, &#xce;le-de-France, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harroche</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Hematology, Haemophilia Treatment Centre, University Hospital Necker Enfants Malades, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lambert</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Clinical immunology, Reference Centre of Autoimmune Systemic Rare Diseases Of North And North-West of France (CeRAINO), U1167 RID-AGE, Lille University, Inserm, University hospital of Lille, 59000 Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Clinical Immunology, Strasbourg University Hospital, Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin-Toutain</LastName><ForeName>I</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Resource and Competence Centre for Haemorrhagic Diseases, Hospital Center of Versailles Andr&#xe9;-Mignot, Le Chesnay, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mathian</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Institut E3M, CIMI-Paris, Faculty of medicine, National Reference Centre of Systemic Lupus, antiphospholipid syndrome, and other autoimmune diseases, Sorbonne University, AP-HP, Piti&#xe9; Salp&#xea;tri&#xe8;re, boulevard de l'H&#xf4;pital, 75013 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mekinian</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Inflammation-Immunopathology-Biotherapy (DMU i3), Saint-Antoine Hospital, Sorbonne University, AP-HP, 75012 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pineton De Chambrun</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Institut E3M, CIMI-Paris, Faculty of medicine, National Reference Centre of Systemic Lupus, antiphospholipid syndrome, and other autoimmune diseases, Sorbonne University, AP-HP, Piti&#xe9; Salp&#xea;tri&#xe8;re, boulevard de l'H&#xf4;pital, 75013 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Pontual</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Paediatrics, Jean-Verdier Hospital, AP-HP, HUPSSD, 93140 Bondy, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wahl</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Vascular Medicine Division and Regional Competence Centre for Rare Vascular and Systemic Autoimmune Diseases, CHRU de Nancy, Nancy, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yelnik</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Clinical immunology, Reference Centre of Autoimmune Systemic Rare Diseases Of North And North-West of France (CeRAINO), U1167 RID-AGE, Lille University, Inserm, University hospital of Lille, 59000 Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zuily</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Vascular Medicine Division and Regional Competence Centre for Rare Vascular and Systemic Autoimmune Diseases, CHRU de Nancy, Nancy, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Collaborators</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Rev Med Interne</MedlineTA><NlmUniqueID>8101383</NlmUniqueID><ISSNLinking>0248-8663</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017152">Antibodies, Antiphospholipid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016736" MajorTopicYN="Y">Antiphospholipid Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017152" MajorTopicYN="N">Antibodies, Antiphospholipid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013927" MajorTopicYN="Y">Thrombosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001327" MajorTopicYN="Y">Autoimmune Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antiphospholipid syndrome</Keyword><Keyword MajorTopicYN="N">Catastrophic antiphospholipid syndrome</Keyword><Keyword MajorTopicYN="N">Catastrophique syndrome des antiphospholipides</Keyword><Keyword MajorTopicYN="N">Management</Keyword><Keyword MajorTopicYN="N">Prise en charge</Keyword><Keyword MajorTopicYN="N">Syndrome des antipohospholipides</Keyword><Keyword MajorTopicYN="N">Traitement</Keyword><Keyword MajorTopicYN="N">Treatment</Keyword></KeywordList><InvestigatorList><Investigator ValidYN="Y"><LastName>Chauveau</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Nephrology, Toulouse, France.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Clouscard</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Association Lupus France, France.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Frere</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Haematology, Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Hachulla</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Internal Medicine, Lille, France.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Kone-Paut</LastName><ForeName>I</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Paediatric Rheumatology, Kremlin Bic&#xea;tre, France.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Lasne</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Haematology, Necker, Paris, France.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Lecompte</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Haematology, Nancy, France.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Le Guern</LastName><ForeName>V</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Internal Medicine, Cochin, Paris, France.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Ni Zard</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Gynaecology-Obstetrics, Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Papo</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Internal Medicine, Bichat, Paris, France.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Riviere</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>French Association of Lupus and Other Autoimmune Diseases, France.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Schleinitz</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Internal Medicine, Marseille, France.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Tossier</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>General Medicine, Tourcoing, France.</Affiliation></AffiliationInfo></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>22</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>21</Day><Hour>21</Hour><Minute>55</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37735010</ArticleId><ArticleId IdType="doi">10.1016/j.revmed.2023.08.004</ArticleId><ArticleId IdType="pii">S0248-8663(23)00711-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>